Mitotic Inhibitor Medications (Vinca Alkaloids)

NCLEX Review Guide: Mitotic Inhibitor Medications (Vinca Alkaloids)

Overview of Vinca Alkaloids

Mechanism of Action

Vinca alkaloids are mitotic inhibitors that bind to tubulin proteins, preventing formation of microtubules essential for cell division during the M phase of mitosis.
These medications cause metaphase arrest, leading to cancer cell death by disrupting the mitotic spindle formation required for chromosome separation.

Key Points

Target rapidly dividing cells (cancer cells and normal cells like hair follicles, GI tract, bone marrow)
Cell cycle specific - work during M phase (mitosis)
Derived from the Madagascar periwinkle plant

Common Vinca Alkaloids

Primary Medications

Vincristine (Oncovin) - Used for lymphomas, leukemias, and pediatric cancers with primary toxicity being peripheral neuropathy.
Vinblastine (Velban) - Used for Hodgkin's lymphoma and testicular cancer with primary toxicity being bone marrow suppression.
Vinorelbine (Navelbine) - Used primarily for non-small cell lung cancer and breast cancer.

Vinca Alkaloid Comparison

Drug	Primary Use	Major Toxicity
Vincristine	Lymphomas, ALL	Peripheral neuropathy
Vinblastine	Hodgkin's lymphoma	Bone marrow suppression
Vinorelbine	Lung/breast cancer	Neutropenia

Administration and Safety

Critical Administration Guidelines

NEVER administer intrathecally - Fatal neurotoxicity occurs with intrathecal administration of vinca alkaloids.
Administer intravenously only through patent IV line to prevent extravasation and tissue necrosis.
Use vesicant precautions including central line when possible and immediate treatment protocols for extravasation.

Verify IV patency before administration
Administer through central line or large peripheral vein
Monitor injection site continuously during infusion
Have extravasation kit readily available
Document administration site and patient response

Memory Aid

"VINCA = Very Important Never Confuse Administration"

V - Vesicant (causes tissue damage)
I - Intravenous ONLY
N - Never intrathecal
C - Central line preferred
A - Always monitor for extravasation

Adverse Effects and Nursing Considerations

Major Side Effects

Peripheral neuropathy (especially vincristine) - Monitor for numbness, tingling, decreased reflexes, and difficulty with fine motor skills.
Bone marrow suppression (especially vinblastine) - Monitor CBC, assess for infection signs, bleeding, and fatigue.
Alopecia - Provide emotional support and education about temporary hair loss.
Constipation - Implement bowel regimen and dietary modifications to prevent paralytic ileus.

Clinical Scenario

A patient receiving vincristine reports difficulty buttoning shirts and decreased sensation in fingertips. The nurse should:

Assess neurological status including reflexes and sensation
Document findings and notify oncologist
Provide safety education about fall risk
Consider occupational therapy referral

Key Points

Vincristine causes more neuropathy, vinblastine causes more myelosuppression
Neuropathy may be irreversible with prolonged use
SIADH can occur, monitor sodium levels

Commonly Confused Points

Vinca Alkaloids vs Other Mitotic Inhibitors

Aspect	Vinca Alkaloids	Taxanes
Mechanism	Prevent microtubule formation	Stabilize microtubules
Administration	IV bolus or short infusion	Longer IV infusion
Premedication	Usually not required	Required (steroids, antihistamines)
Major toxicity	Neuropathy (vincristine)	Hypersensitivity reactions

Memory Aid for Toxicities

"VINCRISTINE = NERVES, VINBLASTINE = BLOOD"

Vincristine affects the nervous system primarily
Vinblastine affects the blood/bone marrow primarily

Study Tips and Quick Checks

NCLEX Success Strategies

Remember the "VIN" prefix indicates vinca alkaloid - always think about neuropathy and extravasation risks.
When you see peripheral neuropathy in cancer patients, think vincristine as the most likely cause.
For administration questions, intrathecal administration is NEVER correct for vinca alkaloids.

Quick Assessment Checklist

Patient education about neuropathy symptoms completed
IV site assessed for patency before administration
Extravasation kit available at bedside
Baseline neurological assessment documented
CBC monitoring schedule established
Bowel regimen initiated for constipation prevention

Common Pitfalls

Don't confuse vincristine (more neuropathy) with vinblastine (more myelosuppression)
Never select intrathecal as an administration route
Remember that neuropathy can be dose-limiting and potentially irreversible
Don't forget to assess for SIADH, especially with vincristine

다음 이론을 계속 학습하려면 로그인하세요.

로그인하고 계속 학습

제안하기

컨텐츠 수정하기

Mitotic Inhibitor Medications (Vinca Alkaloids)

NCLEX Review Guide: Mitotic Inhibitor Medications (Vinca Alkaloids)

Overview of Vinca Alkaloids

Mechanism of Action

Key Points

Common Vinca Alkaloids

Primary Medications

Vinca Alkaloid Comparison

Administration and Safety

Critical Administration Guidelines

Memory Aid

Adverse Effects and Nursing Considerations

Major Side Effects

Clinical Scenario

Key Points

Commonly Confused Points

Vinca Alkaloids vs Other Mitotic Inhibitors

Memory Aid for Toxicities

Study Tips and Quick Checks

NCLEX Success Strategies

Quick Assessment Checklist

Common Pitfalls

오늘의 열정을 계속 이어가세요!

제안하기

컨텐츠 수정하기

Mitotic Inhibitor Medications (Vinca Alkaloids)

NCLEX Review Guide: Mitotic Inhibitor Medications (Vinca Alkaloids)

Overview of Vinca Alkaloids

Mechanism of Action

Key Points

Common Vinca Alkaloids

Primary Medications

Vinca Alkaloid Comparison

Administration and Safety

Critical Administration Guidelines

Memory Aid

Adverse Effects and Nursing Considerations

Major Side Effects

Clinical Scenario

Key Points

Commonly Confused Points

Vinca Alkaloids vs Other Mitotic Inhibitors

Memory Aid for Toxicities

Study Tips and Quick Checks

NCLEX Success Strategies

Quick Assessment Checklist

Common Pitfalls